Thyroid Autoimmunity and Environment

Abstract

Autoimmune thyroid disorders (AITDs) are the result of a complex interplay between genetic and environmental factors, the former account for about 70–80% of liability to develop AITDs. However, at least 20–30% is contributed by environmental factors, which include certainly smoking (at least for Graves’ disease and orbitopathy), probably stress, iodine and selenium intake, several drugs, irradiation, pollutants, viral and bacterial infections, allergy, pregnancy, and post-partum. Evidence for the intervention of these factors is often limited, and the mechanisms whereby environmental factors may concur to the onset of AITDs are in many instances unclear. Nevertheless, gene-environment interaction seems a fundamental process for the occurrence of AITDs.

thyroid autoimmunity - iodine - selenium - stress - smoking - interferon-α - IL-2 - amiodarone - pollutants - infections - pregnancy

References

• 1 Weetman AP, MacGregor AM. Autoimmune thyroid disease: further developments in our understanding.  Endocr Rev. 1994;  15 788-830
• 2 Weetman AP. Autoimmune thyroid disease: propagation and progression.  Eur J Endocrinol. 2003;  148 1-9
• 3 Pearce SHS, Kendall-Taylor P. Genetic factors in thyroid disease. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid – A Fundamental and Clinical Text, 9th ed. Philadelphia: Lippincott Williams & Wilkins 2005: 407-421
• 4 Taylor JC, Gough SC, Hunt PJ, Brix TH, Chatterjee K, Connell JM, Franklyn JA, Hegedus L, Robinson BG, Wiersinga WM, Wass JA, Zabaneh D, Mackay I, Weetman AP. A genome wide-screen in 1119 relative pairs with autoimmune thyroid disease.  J Clin Endocrinol Metab. 2006;  91 646-653
• 5 Prummel MF, Wiersinga WM. Smoking and risk of Graves’ disease.  JAMA. 1993;  269 479-482
• 6 Vestergaard P, Rejnmark L, Weeke J, Hoeck HC, Nielsen HK, Rungby J, Laurberg P, Mosekilde L. Smoking as a risk factor for Graves’ disease, toxic nodular goiter and autoimmune hypothyroidism.  Thyroid. 2002;  12 69-75
• 7 Glinoer D, De Nayer P, Bex M. and the Belgian Collaborative Study Group on Graves’ Disease . Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.  Eur J Endocrinol. 2001;  144 475-483
• 8 Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR. Does smoking increase relapse rates in Graves’ disease?.  J Endocrinol Invest. 2002;  25 152-157
• 9 Bartalena L, Marcocci C, Pinchera A. Cigarette smoking and thyroid eye disease. In: Dutton JJ, Haik BG , eds. Thyroid Disease – Diagnosis and Treatment. New York: Marcel Dekker Inc 2002: 251-259
• 10 Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, Loviselli A, Pinchera A. More on smoking habits and Graves’ ophthalmopathy.  J Endocrinol Invest. 1989;  12 733-737
• 11 Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell’Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A. Cigarette smoking and treatment outcomes in Graves’ ophthalmopathy.  Ann Intern Med. 1998;  129 632-635
• 12 Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. The effects of tumour necrosis factor-α and interleukin 1 on an in vitro model of thyroid-associated ophthalmopathy; contrasting effects on adipogenesis.  Eur J Endocrinol. 2006;  155 395-403
• 13 Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link.  J Clin Endocrinol Metab. 2007;  92 59-64
• 14 Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy.  Clin Endocrinol (Oxf). 1994;  40 67-72
• 15 Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli M, Stahl M, von Arx G, Wiersinga WM. Consensus statement of European Group on Graves’ Orbitopathy (EUGOGO) on management of GO.  Eur J Endocrinol. 2008;  158 273-285
• 16 Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM. Consensus statement of European Group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy.  Thyroid. 2008;  18 333-346
• 17 Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption.  Clin Endocrinol (Oxf). 1996;  45 477-481
• 18 Vestergaard P. Smoking and thyroid disorders – a meta-analysis.  Eur J Endocrinol. 2002;  146 153-161
• 19 Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III).  J Clin Endocrinol Metab. 2004;  89 6077-6086
• 20 Strieder TG, Prummel MF, Tijssen JG, Endert E, Wiersinga WM. Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease.  Clin Endocrinol (Oxf). 2003;  59 396-401
• 21 Mizokami T, Wu Li A, El-Kaissi S, Wall JR. Stress and thyroid autoimmunity.  Thyroid. 2003;  14 1047-1055
• 22 Chiovato L, Pinchera A. Stressful life events and Graves’ disease.  Eur J Endocrinol. 1996;  134 680-682
• 23 Matos-Santos A, Nobre EL, Costa JG, Nogueira PJ, Macedo A, Galvão-Teles A, de Castro JJ. Relationship between the number and impact of stressful life events and the onset of Graves’ disease and toxic nodular goiter.  Clin Endocrinol (Oxf). 2001;  55 15-19
• 24 Sonino N, Girelli ME, Boscaro M, Fallo F, Busnardo B, Fava GA. Life events in the pathogenesis of Graves’ disease. A controlled study.  Acta Endocrinol (Copenh). 1993;  128 293-296
• 25 Winsa B, Adami H, Bergström R, Gamstedt A, Dahlberg PA, Adamson U, Jansson R, Karlsson A. Stressful life events and Graves’ disease.  Lancet. 1991;  338 1475-1479
• 26 Paunkovic N, Paunkovic J, Pavlovic O, Paunovic Z. The significant increase in incidence of Graves’ disease in eastern Serbia during the civil war in the former Yugoslavia (1992 to 1995).  Thyroid. 1998;  8 37-41
• 27 Chiovato L, Marinò M, Perugi G, Fiore E, Montanelli L, Lapi P, Cavaliere R, Ciampi M, Patronelli A, Placidi G, Placidi GF, Cassano GB, Pinchera A. Chronic recurrent stress due to panic disorder does not precipitate Graves’ disease.  J Endocrinol Invest. 1998;  21 758-764
• 28 Fukao A, Takamatsu J, Murakami Y, Sakane S, Miyauchi A, Kuma K, Hayashi S, Hanafusa T. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves’ disease.  Clin Endocrinol (Oxf). 2003;  58 550-555
• 29 Dayan CM. Stressful events and Graves’ disease revisited.  Clin Endocrinol (Oxf). 2001;  55 13-14
• 30 Liu C, Papewalis C, Domberg J, Scherbaum WA, Schott M. Chemo-kines and autoimmune thyroid diseases.  Horm Metab Res. 2008;  40 361-368
• 31 Domberg J, Chao L, Papewalis C, Pfleger C, Xu K, Willenberg HS, Hermsen D, Scherbaum WA, Schloot NC, Schott M. Circulating chemokines in patients with autoimmune thyroid diseases.  Horm Metab Res. 2008;  40 416-421
• 32 Martin-du Pan RC. Triggering role of stress and pregnancy in the occurrence of 98 cases of Graves’ disease compared to 95 cases of Hashimoto thyroiditis and 97 cases of thyroid nodules.  Ann Endocrinol (Paris). 1998;  59 107-112
• 33 Oretti RG, Harris B, Lazarus JH, Parkes AB, Crownshaw T. Is there an association between life events, postnatal depression and thyroid dysfunction in thyroid antibody positive women?.  Int J Soc Psychiatry. 2003;  49 70-76
• 34 Strieder TG, Prummel MF, Tijssen JG, Brosschot JF, Wiersinga WM. Stress is not associated with thyroid peroxidase autoantibodies in euthyroid women.  Brain Behav Immun. 2005;  19 203-206
• 35 Ruwhof C, Drexhage HA. Iodine and thyroid autoimmune disease in animal models.  Thyroid. 2001;  11 427-436
• 36 Rose NR, Bonita R, Burek CL. Iodine: an environmental trigger of thyroiditis.  Autoimm Rev. 2002;  1 97-103
• 37 Allen EM, Appel MC, Braverman LE. The effect of iodide ingestion on the development of spontaneous lymphocytic thyroiditis in diabetes-prone BB/W rat.  Endocrinology. 1986;  118 1977-1981
• 38 Mariotti S, Pinna G. Autoimmune thyroid diseases. In: Braverman LE ed. Diseases of the Thyroid, 2nd ed. Totowa: Humana Press Inc 2003: 107-160
• 39 Laurberg P, Pedersen KM, Hreidarsson A, Sigfusson N, Iversen E, Knudsen PR. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and Jutland, Denmark.  J Clin Endocrinol Metab. 1998;  83 765-769
• 40 Laurberg P, Nohr SB, Pedersen KM, Sigfusson N, Iversen E, Knudsen PR. Thyroid disorders in mild iodine deficiency.  Thyroid. 2000;  10 951-963
• 41 Mostbeck A, Galvan G, Bauer P, Eber O, Atefie K, Dam K, Feichtiger H, Fritzsche H, Haydl H, Köhn H, König B, Koriska K, Kroiss A, Lind P, Markt B, Maschek W, Pesl H, Ramschak-Schwarzer S, Riccabona G, Stockhammer M, Zechmann W. The incidence of hyperthyroidism in Austria from 1987 to 1995 before and after an increase in salt iodization.  Eur J Nucl Med. 1998;  25 367-374
• 42 Tsatsoulis A, Johnson EO, Andricula M, Kalogera C, Svarna E, Spyroy P, Seferiadis K, Tsolas O. Thyroid autoimmunity is associated with higher urinary iodine concentrations in an iodine-deficient area of Northwestern Greece.  Thyroid. 1999;  9 279-283
• 43 Roti E, degli Uberti E. Iodine excess and hyperthyroidism.  Thyroid. 2001;  11 493-500
• 44 Wiersinga WM, Braverman LE. Iodine-induced thyroid disease. In: Braverman LE, ed. Diseases of the Thyroid, 2nd ed. Totowa: Humana Press 2003: 347-362
• 45 Rayman MP. The importance of selenium to human health.  Lancet. 2000;  356 233-241
• 46 Köhrle J, Jakob F, Contempré B, Dumont JE. Selenium, the thyroid, and the endocrine system.  Endocr Rev. 2005;  26 944-984
• 47 Zimmermann MB, Köhrle J. The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health.  Thyroid. 2002;  12 867-878
• 48 Derumeaux H, Valeix P, Castetbon K, Bensimon M, Boutron-Rouault MC, Arnaud J, Herchberg S. Association of selenium with thyroid volume and echostructure in 35- to 60-year-old French adults.  Eur J Endocrinol. 2003;  148 309-315
• 49 Spallholz JE, Boylan LM, Larsen HS. Advances in understanding selenium's role in the immune system.  Ann NY Acad Sci. 1990;  587 123-129
• 50 Gärtner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations.  J Clin Endocrinol Metab. 2002;  87 1687-1691
• 51 Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with seleniomethionine in patients with autoimmune thyroiditis.  Eur J Endocrinol. 2003;  148 389-393
• 52 Turker O, Kumanlioglu K, Karapolat I, Dogan I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses.  J Endocrinol. 2006;  190 151-156
• 53 Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, Ganotakis ES. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO levels in patients with Hashimoto's thyroiditis.  Thyroid. 2007;  17 609-612
• 54 Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies.  J Clin Endocrinol Metab. 2007;  92 1263-1268
• 55 Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid.  Endocr Rev. 2001;  22 240-254
• 56 Bogazzi F, Bartalena L, Gasperi M, Braverman LE, Martino E. The various effects of amiodarone on thyroid function.  Thyroid. 2001;  11 511-519
• 57 Monteiro E, Galvão-Teles A, Santos ML, Mourão L, Correia MJ, Lopo Tuna J, Ribeiro C. Antithyroid antibodies as an early marker for thyroid disease induced by amiodarone.  Br Med J. 1986;  292 227-278
• 58 Loviselli A, Bartalena L, Balzano S, Aghini-Lombardi F, Sica V, Pilosu R, Petrini L, Giannessi G, Buratti L, Martino E. Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone.  J Endocrinol Invest. 1988;  11 323-325
• 59 Safran M, Martino E, Aghini-Lombardi F, Bartalena L, Balzano S, Pinchera A, Braverman LE. Effect of amiodarone on circulating antithyroid antibodies.  Br Med J. 1988;  297 456-457
• 60 Weetman AP, Bhandal SK, Burrin JM, Robinson K, MacKenna W. Amiodarone and thyroid autoimmunity in the United Kingdom.  Br Med J. 1988;  297 33-36
• 61 Miller KK, Daniels GH. Association between lithium used and thyrotoxicosis caused by silent thyroiditis.  Clin Endocrinol (Oxf). 2001;  55 501-508
• 62 Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone.  Thyroid. 1998;  8 909-913
• 63 Kirov G, Tredget J, John R, Owen MJ, Lazarus HJ. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients.  J Affect Dis. 2005;  87 313-317
• 64 Nemeroff C, Simon J, Haggerty  Jr  JJ, Evans DL. Antithyroid antibodies in depressed patients.  Am J Psychiatry. 1985;  142 840-843
• 65 Kupka RW, Nolen WA, Post RM, McElroy SL, Altschuler LL, Denikoff KD, Frye MA, KecK  Jr  PE, Leverich GS, Rush AJ, Suppes T, Pollio C, Drexhage HA. High rate of autoimmune thyroiditis in bipolar disorder. Lack of association with lithium exposure.  Biol Psychiatry. 2002;  51 305-311
• 66 Wilson R, MacKillop JH, Crocket GT, Pearson C, Jenkins C, Burns F, Burnett AK, Thomson JA. The effect of lithium therapy on parameters thought to be involved in the development of autoimmune thyroid disease.  Clin Endocrinol (Oxf). 1991;  34 357-361
• 67 Baethge C, Blumentritt H, Berghöfer A, Bschor T, Glenn T, Adli M, Schlattmann P, Bauer M, Finke R. Long-term lithium treatment and thyroid antibodies: a controlled study.  J Psychiatry Neurosci. 2005;  30 423-427
• 68 Bocchetta A, Cocco F, Velluzzi F, Del Zompo M, Mariotti S, Loviselli A. Fifteen-year follow-up of thyroid function in lithium patients.  J Endocrinol Invest. 2007;  30 363-366
• 69 Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.  N Engl J Med. 1988;  318 1557-1563
• 70 Chianese-Bullock KA, Woodson EM, Tao H, Boerner SA, Smolkin M, Grosh WW, Neese PY, Merrill P, Petroni GR, Slingluff  Jr  CL. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.  J Immunother. 2005;  28 412-419
• 71 Prummel MF, Laurberg P. Interferon-α and autoimmune thyroid disease.  Thyroid. 2003;  13 547-551
• 72 Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Interferon-α-related thyroid disease: pathophysiological, epidemiological, and clinical aspects.  J Clin Endocrinol Metab. 2004;  89 3656-3661
• 73 Fernandez-Soto L, González A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, Salmeron J. Increased risk of autoimmune thyroid disease in hepatitis C versus hepatitis B before, during, and after discontinuing interferon therapy.  Arch Intern Med. 1998;  158 1445-1448
• 74 Marazuela M, García-Buey L, González-Fernández B, García-Monzón C, Arranz A, Borque MJ, Moreno-Otero R. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy.  Clin Endocrinol (Oxf). 1996;  44 635-642
• 75 Woitas RP, Stoschus B, Terjung B, Vogel M, Kupfer B, Brackmann HH, Rockstroh JK, Sauerbruch T, Spengler U. Hepatitis C-associated autoimmunity in patients coinfected with HIV.  Liver Int. 2005;  25 1114-1121
• 76 Gilquin J, Viard JP, Jubault V, Sert C, Kazatchkine MD. Delayed occurrence of Graves’ disease after immune restoration with HAART.  Lancet. 1998;  352 1907-1908
• 77 Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, Kazatchkine MD, Gilquin J, Viard JP. Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromized human immunodeficiency virus-1-infected patients.  J Clin Endocrinol Metab. 2000;  85 4254-4257
• 78 Chen F, Day SL, Metcalfe RA, Sethi G, Kapembwa MS, Brook MJ, Churchill D, de Ruiter A, Robinson S, Lacey CJ, Weetman AP. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease.  Medicine. 2005;  84 98-106
• 79 Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Solinas P, Mannazzu M, Falchi A, Mura MS, Madeddu G. Thyroid function in human immunodeficiency virus patients with highly active antiretroviral therapy (HAART): a longitudinal study.  Clin Endocrinol (Oxf). 2006;  64 375-383
• 80 Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.  Lancet. 1999;  354 1691-1695
• 81 Eheman CR, Garbe P, Tuttle RM. Autoimmune thyroid disease associated with environmental thyroidal irradiation.  Thyroid. 2003;  13 453-464
• 82 Pacini F, Vorontsova T, Molinaro E, Kuchinskaya E, Agate L, Shavrova E, Astachova L, Chiovato L, Pinchera A. Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout.  Lancet. 1998;  352 763-766
• 83 Vermiglio F, Castagna MG, Volnova E, Lo Presti VP, Moleti M, Violi Ma, Artemisia A, Trimarchi F. Post-Chernobyl increased prevalence of humoral thyroid autoimmunity in children and adolescents from a moderately iodine-deficient area in Russia.  Thyroid. 1999;  9 781-786
• 84 Tronko MD, Brenner AV, Olijnyk VA, Robbins J, Epstein OV, MacConnel RJ, Bogdanova TI, Fink DJ, Likhatarev IA, Lubin JH, Markov VV, Bouville AC, Terekhova GM, Zablotska LB, Shpak VM, Brill AB, Tereshchenko VP, Masnyk IJ, Ron E, Hatch M, Howe GR. Autoimmune thyroiditis and exposure to iodine 131 in the Ukrainian Cohort Study of thyroid cancer and other thyroid diseases after the Chornobyl accident: results from the first screening cycle (1998–2000).  J Clin Endocrinol Metab. 2006;  91 4344-4351
• 85 Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, Greffe B, Wolden S, Robinson L. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the childhood cancer survivor study.  J Clin Endocrinol Metab. 2000;  85 3227-3232
• 86 Nygaard B, Metcalfe RA, Phipps J, Weetman AP, Hegedüs L. Graves’ disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter.  J Endocrinol Invest. 1999;  22 481-485
• 87 Bartalena L, Bogazzi F, Pecori F, Martino E. Graves’ disease occurring after subacute thyroiditis: report of a case and review of the literature.  Thyroid. 1996;  6 345-348
• 88 Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy.  N Engl J Med. 1998;  338 73-78
• 89 Hagmar L. Polychlorinated biphenyls and thyroid status in humans: a review.  Thyroid. 2003;  13 1021-1028
• 90 Siddiqi MA, Laessig RH, Reed KD. Polybrominated diphenyl ethers (PBDEs): new pollutants-old diseases.  Clin Med Res. 2003;  1 281-290
• 91 Boas M, Feldt-Rasmussen U, Skakkebaek NE, Main KM. Environmental chemicals and thyroid function.  Eur J Endocrinol. 2006;  154 599-611
• 92 Langer P, Tajtáková M, Fodor G, Kocan A, Bohov P, Michálek J, Kreze A. Increased thyroid volume and prevalence of thyroid disorders in an area heavily polluted by polychlorinated biphenyls.  Eur J Endocrinol. 1998;  139 402-409
• 93 Langer P, Tajtáková M, KOcan A, Petrik J, Koska J, Ksinantovà L, Radikovà Z, Ukropec J, Imrich R, Huckova M, Chovancovà J, Drobnà B, Jursa S, Vicek M, Bergman A, Athanasiadou M, Hovander L, Shishiba Y, Trnovec T, Sebokovà E, Klimes I. Thyroid ultrasound volume, structure and function after long-term exposure of large population to polychlorinated biphenyls.  Chemosphere. 2007;  69 118-127
• 94 Langer P, Kocan A, Tajtáková M, Koska J, Rádiková A, Ksinantová L, Imrich R, Hucková M, Drobná B, Gasperíková D, Seböková E, Klimes I. Increased thyroid volume, prevalence of thyroid antibodies and impaired fasting glucose in young adults from organochlorine cocktail polluted area: outcome of transgenerational transmission?.  Chemosphere. 2008;  73 1145-1150
• 95 Rueda FL, Palomares JM, Rico IV. Atypical thyroiditis in Huelva, Spain.  Endocr Pract. 1999;  5 109-113
• 96 Tomer Y, Davies TF. Infection, thyroid disease, and autoimmunity.  Endocr Rev. 1993;  14 107-120
• 97 Strieder TG, Wenzel BE, Prummel MF, Tujssen JG, Wiersinga WM. Increased prevalence of antibodies to enteropathogenic Yersinia enterocolitica virulence proteins in relatives of patients with autoimmune thyroid disease.  Clin Exp Immunol. 2003;  132 278-282
• 98 Prummel MF, Strieder T, Wiersinga WM. The environment and autoimmune thyroid diseases.  Eur J Endocrinol. 2004;  150 605-618
• 99 Chatzipanagiotou S, Legakis JN, Boufidou F, Petroyanni V, Nicolaou C. Prevalence of Yersinia plasmid-encoded outer protein (YOP) class-specific antibodies in patients with Hashimoto's thyroiditis.  Clin Microbiol Infect. 2001;  7 138-143
• 100 Corapcioğ;lu D, Tonyukuk V, Kiyan M, Yilmaz AE, Emral R, Kamel N, Erdoğan G. Relationship between thyroid autoimmunity and Yersinia enterocolitica antibodies.  Thyroid. 2002;  12 613-617
• 101 Wenzel BE, Heesemann J, Heufelder A, Francke TF, Grammerstorf S, Stemerowicz R, Hopf U. Enteropathogenic Yersinia enterocolitica and organ-specific autoimmune diseases in man.  Contrib Microbiol Immunol. 1991;  12 80-88
• 102 Bloomfield SF, Stanwell-Smith R, Crevel RW, Pickup J. Too clean, or not to clean: the hygiene hypothesis and home hygiene.  Clin Exp Allergy. 2006;  36 402-425
• 103 Kondrashova A, Reunanen A, Romanov A, Karvonen A, Viskari H, Vesikari T, Ilonen J, Knip M, Hyöty H. Serological evidence of thyroid autoimmunity among school children in two different socioeconomic environments.  J Clin Endocrinol Metab. 2008;  93 729-734
• 104 Davies TF. Infection and autoimmune thyroid disease.  J Clin Endocrinol Metab. 2008;  93 674-676
• 105 Davies TF. The thyroid immunology of the postpartum period.  Thyroid. 1999;  9 675-684
• 106 Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V. Parity and the risk of autoimmune thyroid disease: a community-based study.  J Clin Endocrinol Metab. 2005;  90 5309-5312
• 107 Bülow Pedersen I, Laurberg P, Knudsen N, Jørgensen T, Perrild H, Ovesen L, Rasmussen LB. Lack of association between thyroid autoantibodies and parity in a population study argues against microchimerism as a trigger of thyroid autoimmunity.  Eur J Endocrinol. 2006;  154 39-45
• 108 Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years post-partum.  Proc Natl Acad Sci USA. 1996;  93 705-708
• 109 Ando T, Imaizumi M, Graves PN, Unger P, Davies TF. Intrathyroidal fetal microchimerism in Graves’ disease.  J Clin Endocrinol Metab. 2002;  87 3315-3320
• 110 Klintschar M, Immel U-D, Kehlen A, Schwaiger P, Mustafa T, Mannweiler S, Regauer S, Kleiber M, Hoang-Vu C. Fetal microchimerism in Hashimoto's thyroiditis: a quantitative approach.  Eur J Endocrinol. 2006;  154 237-241
• 111 Srivatsa B, Srivatsa S, Johnson KL, Samura O, Lee SL, Bianchi DW. Microchimerism of presumed fetal origin in thyroid specimens from women: a case-control study.  Lancet. 2001;  358 2034-2038
• 112 Ando T, Davies TF. Postpartum autoimmune thyroid disease: the potential role of fetal microchimerism.  J Clin Endocrinol Metab. 2003;  88 2965-2971
• 113 Brix TH, Kyvik KO, Christensen K, Hegedüs L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts.  J Clin Endocrinol Metab. 2001;  86 930-934

Correspondence